View Clinical Trial (Medical Research Study)

Curcumin in Pediatric Inflammatory Bowel Disease - NCT00889161-98105(Clinical Trial 333981)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Seattle
State:  
WA
Zip Code: 98105
Conditions: Inflammatory Bowel Disease - Ulcerative Colitis - Crohn's Disease
Purpose: This is a single center, open label forced dose titration study designed to determine the tolerability of curcumin in pediatric patients with inflammatory bowel disease (IBD). This study will provide initial tolerability and safety data in pediatric patients with IBD. Twenty patients with IBD in remission or with mild disease (score <34 on PUCAI or score <30 on the PCDAI) on sulfasalazine or mesalamine aged 8 to 18 years will be enrolled into this study. Each patient will participate in the study for nine weeks. From this study an appropriate dosage will be determined to proceed with a double blinded placebo controlled study.
Study summary:
Criteria: Inclusion Criteria: - Children and adolescents eight to eighteen years old - Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology - Mild disease or in clinical remission based upon PUCAI or PCDAI score (score <34 on the PUCAI or score <30 on the PCDAI) - Parent/guardian and participant must be able to attend study visits at screening, baseline, and weeks three, six, and nine - Patient must be on a stable dose of IBD medications for at least 3 months - Patient must be able to swallow study medication Exclusion Criteria: - Abnormal laboratory values as defined in the protocol - History of increased gastrointestinal symptoms ("flare") in the last 3 months - Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD - Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil). Allowed supplementation includes multivitamin, vitamin D & calcium, folate and vitamin B12, and Iron. - Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease. - History of gastrointestinal surgery or planned gastrointestinal surgery in the future. - Tobacco, alcohol, or illicit drug abuse - Planned surgery during the potential study participation time - Inability to swallow study medication
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 16, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.